NRAS Q61H
|
HCC
|
NRAS Q61H
|
HCC
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
sorafenib + BAY86-9766 Sensitive: C3 – Early Trials
|
NRAS Q61H
|
Melanoma
|
NRAS Q61H
|
Melanoma
|
nivolumab Sensitive: C3 – Early Trials
|
nivolumab Sensitive: C3 – Early Trials
|
NRAS Q61H
|
Melanoma
|
NRAS Q61H
|
Melanoma
|
ipilimumab Sensitive: C4 – Case Studies
|
ipilimumab Sensitive: C4 – Case Studies
|
NRAS Q61H
|
Multiple Myeloma
|
NRAS Q61H
|
Multiple Myeloma
|
bortezomib Sensitive: D – Preclinical
|
bortezomib Sensitive: D – Preclinical
|